Alembic Pharmaceuticals Limited

rs,

: 7th November, 2023 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code:533573 To, The Manager, Listing Department, N

8%

nd failure to gain market acceptance. Quarterly Snapshot INR Bn Key Highlights : Revenue 15.95 8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2%

7%

re to gain market acceptance. Quarterly Snapshot INR Bn Key Highlights : Revenue 15.95 8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13%

6%

y Snapshot INR Bn Key Highlights : Revenue 15.95 8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Brand

4%

ot INR Bn Key Highlights : Revenue 15.95 8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Busin

14%

ghts : Revenue 15.95 8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Business : India Branded Bus

2%

8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Business : India Branded Business recorded 5% gro

13%

7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Business : India Branded Business recorded 5% growth with

9%

BIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Business : India Branded Business recorded 5% growth with topline of Rs 5.77 Bn for

5%

37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Business : India Branded Business recorded 5% growth with topline of Rs 5.77 Bn for Q2 FY24. US Generics : Growth of 14% on sequential basis is

Rs 5.77

rofit Margin 9% India Branded Business : India Branded Business recorded 5% growth with topline of Rs 5.77 Bn for Q2 FY24. US Generics : Growth of 14% on sequential basis is driven by new launches and mark

17%

to drive growth in upcoming quarters. Ex-US Generics : Momentum continued for Q2 as well with a 17% growth on YoY basis. Demand outlook remains strong. Product registrations as well as dossier exte

“Product registrations as well as dossier extensions to new markets are on track to accelerate growth.”

“Anticipate continued growth in API business for upcoming quarters backed by robust order book.”

Key Highlights

1

Targets

1

Investor Relations Advisors

1

Key Highlights

Revenue 15.95 8% YoY 7% QoQ R&D 8% of Sales EBIDTA 2.18 -6% YoY 4% QoQ EBIDTA Margin 14% Net Profit 1.37 2% YoY 13% QoQ Net Profit Margin 9% India Branded Business : India Branded Business recorded 5% growth with topline of Rs 5.77 Bn for Q2 FY24. US Generics : Growth of 14% on sequential basis is driven by new launches and market share gain in few existing products. Launches from new facilities to drive growth in upcoming quarters. Ex-US Generics : Momentum continued for Q2 as well with a 17% growth on YoY basis. Demand outlook remains strong. Product registrations as well as dossier extensions to new markets are on track to accelerate growth. API : Steady business delivering growth of 10% at Q2 level, largely led by high off-take and better product mix. Anticipate continued growth in API business for upcoming quarters backed by robust order book. India branded business driving growth Business Q2 FY24 Q2 FY23 Y-o-Y Q1FY24 Q-o-Q H1 FY24 H1 FY23 Y-o-Y Formulations India US Ex-US API 5.7

Targets

➢ Net-Zero by 2040 ➢ Water Neutrality by 2027 ➢ Plant 50,000 trees by 2027 Strategic Roadmap Business Initiatives in FY23 Plan for FY24 The India Business The US Generics Business The RoW Generics Business • • Strengthened the presence in specialty therapies with the launch of novel products Increased focus on the animal health space with therapy leading products. Launched 18 products • • Received approval for 22 products • Filed 20 ANDAs • • • • Create new marketing division for increasing sales volumes from high-growth therapies Introduce Data Analytics into onfield operations Invest in a new facility which will drive business growth Increase the launch of injectable products • Introduce oncology products in the market • Grow the product basket for dermatology and ophthalmology therapies • • Established a physical presence in Chile and UAE to serve these markets better Strengthened presence in Canada Establish an office in Mexico • • Grow presence in the MENA region Company Overview

Investor Relations Advisors

Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com